XORTX Therapeutics Files Q3 2025 Financial Report
Ticker: XRTX · Form: 6-K · Filed: Nov 17, 2025 · CIK: 1729214
Sentiment: neutral
Topics: financials, reporting, pharmaceutical
TL;DR
XORTX dropped its Q3 financials, check the numbers for yourself.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on November 17, 2025, reporting its financial results for the period ending September 30, 2025. The filing includes condensed interim consolidated financial statements and management's discussion and analysis for the nine months ended September 30, 2025. The company is a pharmaceutical preparations firm based in Vancouver.
Why It Matters
This filing provides investors with an update on XORTX Therapeutics' financial performance and operational status for the third quarter of 2025, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, XORTX Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250930 — Reporting Period End (Financial results are for the nine months ended on this date.)
- 20251117 — Filing Date (The date the 6-K report was submitted to the SEC.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- November 17, 2025 (date) — Filing Date
- September 30, 2025 (date) — Reporting Period End Date
- 001-40858 (other) — SEC File Number
FAQ
What specific financial details are included in the Condensed Interim Consolidated Financial Statements for the period ending September 30, 2025?
The filing indicates that Exhibit 99.1 contains the Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2025, but the specific details are not provided in the summary text.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K on behalf of XORTX Therapeutics Inc.
What is the SEC file number for XORTX Therapeutics Inc.?
The SEC file number for XORTX Therapeutics Inc. is 001-40858.
What is the primary business of XORTX Therapeutics Inc. according to the filing?
According to the filing, XORTX Therapeutics Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Which exhibits are included with this Form 6-K filing?
The exhibits include Condensed Interim Consolidated Financial Statements (99.1), Management Discussion and Analysis (99.2), CEO Certificate (99.3), and CFO Certificate (99.4).
Filing Stats: 163 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-11-17 16:17:20
Filing Documents
- f6k_111525.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 422KB
- exh_992.htm (EX-99.2) — 246KB
- exh_993.htm (EX-99.3) — 11KB
- exh_994.htm (EX-99.4) — 11KB
- logo.jpg (GRAPHIC) — 16KB
- 0001171843-25-007387.txt ( ) — 719KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: November 14, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2025 99.2 Management Discussion and Analysis for the nine months ended September 30, 2025 99.3 CEO Certificate 99.4 CFO Certificate